Paul Tudor Jones’s BridgeBio Pharma BBIO Stock Holding History

Paul Tudor Jones’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.75M	Buy	+77,170	New	+$5.41M	0.01%	1182
2025 Q3	–	Sell	-124,068	Closed	-$6.05M	–	3355
2025 Q2	$5.36M	Buy	124,068 +32,736	+36%	+$1.19M	0.01%	1052
2025 Q1	$3.16M	Buy	+91,332	New	+$3.08M	0.01%	1048
2024 Q2	–	Sell	-22,164	Closed	-$685K	–	2321
2024 Q1	$685K	Buy	+22,164	New	+$754K	﹤0.01%	1509
2023 Q4	–	Sell	-81,150	Closed	-$2.14M	–	2372
2023 Q3	$2.14M	Buy	+81,150	New	+$2.3M	0.02%	895
2023 Q2	–	Sell	-23,321	Closed	-$387K	–	2427
2023 Q1	$387K	Sell	23,321 -51,187	-69%	-$597K	0.01%	1765
2022 Q4	$568K	Sell	74,508 -5,218	-7%	-$50K	0.01%	1496
2022 Q3	$792K	Buy	+79,726	New	+$828K	0.02%	1075
2022 Q1	–	Sell	-120,372	Closed	-$2.01M	–	2008
2021 Q4	$2.01M	Buy	120,372 +29,679	+33%	+$1.26M	0.03%	620
2021 Q3	$4.25M	Buy	90,693 +43,630	+93%	+$2.34M	0.07%	323
2021 Q2	$2.87M	Buy	+47,063	New	+$2.69M	0.05%	410

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Paul Tudor Jones's BBIO Position: Q2 2026 in Review

Paul Tudor Jones opened a new position in BridgeBio Pharma (BBIO) in Q2 2026: 77,170 shares worth $5.75M. The stake represents 0.01% of the portfolio and ranks #1182 among its holdings. This is a return to the name: Paul Tudor Jones previously reported a position in BBIO as recently as Q2 2025.

Paul Tudor Jones first reported a position in BBIO in Q2 2021 and has held it in 11 quarters since. 471 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Paul Tudor Jones held 77,170 shares of BridgeBio Pharma worth $5.75M as of Q2 2026.
BridgeBio Pharma was a new Paul Tudor Jones position in Q2 2026.
BridgeBio Pharma made up 0.01% of Paul Tudor Jones's portfolio in Q2 2026, its #1182 holding.
Paul Tudor Jones first reported a position in BridgeBio Pharma in Q2 2021 and has held it in 11 quarters since.
471 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.